BiotechTube

YM178 + Placebo + tolterodine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder, Overactive

Conditions

Urinary Bladder, Overactive

Trial Timeline

Jul 24, 2009 → Feb 15, 2010

NCT ID
NCT00966004

About YM178 + Placebo + tolterodine

YM178 + Placebo + tolterodine is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT00966004. Target conditions include Urinary Bladder, Overactive.

What happened to similar drugs?

8 of 20 similar drugs in Urinary Bladder, Overactive were approved

Approved (8) Terminated (0) Active (12)
✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
✅solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
🔄Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
🔄solifenacin succinateAstellas PharmaPhase 3
🔄TamuslosinAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00966004Phase 3Completed

Competing Products

20 competing products in Urinary Bladder, Overactive

See all competitors
ProductCompanyStageHype Score
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
Duloxetine + placeboEli LillyPhase 2
35
DuloxetineEli LillyPhase 2
35
Enfortumab vedotinAstellas PharmaPhase 1
21
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
43
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
39
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaPre-clinical
26
TamuslosinAstellas PharmaPhase 3
40
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40